Program
tozorakimab
Also written as “Tozorakimab”, “MEDI3506” and “Tozorakimab Dose Regimen 1”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Respiratory Distress Syndrome · Bronchitis, Chronic · Diabetic Nephropathies, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 143 open or running | phase 3since Dec 2, 2021 | Mar 1, 2017 | Jun 7, 2027phase 2 · NCT06932263 |
- Named in AstraZeneca’s own pipeline as
tozorakimab
, phase 4, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2017First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT03096795 · 88 enrolled · United Kingdom
- Nov 4, 20192 phase 2 studiesNCT04212169, NCT04170543
- Aug 7, 2020Phase 2 study in AsthmaNCT04570657 · 250 enrolled · United States, Argentina, Germany and more
- Oct 20, 2020Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT04631016 · 137 enrolled · United States, Australia, Canada and more
- Jul 27, 2021Phase 1 study in Healthy VolunteerNCT05070312 · 39 enrolled · China
- Dec 2, 20212 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT05158387, NCT05166889
- Nov 11, 2022Phase 3 study in Respiratory Distress SyndromeNCT05624450 · 3,527 planned · United States, Argentina, Australia and more
- Aug 25, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06040086 · 1,454 enrolled · United States, Argentina, Belgium and more
- Mar 5, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06304961 · 46 enrolled · Germany
- Mar 18, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06897748 · 98 enrolled · Russia
- Apr 1, 2025Phase 2 study in AsthmaNCT06932263 · 540 planned · United States, Argentina, Brazil and more
- Apr 29, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07566195 · 59 planned · France
Ahead
- Jun 7, 2027Primary completion: phase 2 study in AsthmaNCT06932263
- Nov 4, 2027Primary completion: phase 3 study in Respiratory Distress SyndromeNCT05624450
- Dec 29, 2028Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07566195
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07566195Pulmonary Disease, Chronic Obstructive · France | 3 | Recruiting | Dec 29, 2028 | 59 |
| NCT06932263Asthma · United States, Argentina, Brazil and more | 2 | Recruiting | Jun 7, 2027 | 540 |
| NCT06897748Pulmonary Disease, Chronic Obstructive · Russia | 2 | Completed | Apr 21, 2026 | 98 |
| NCT06304961Pulmonary Disease, Chronic Obstructive · Germany | 1 | Completed | Sep 9, 2024 | 46 |
| NCT06040086Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more | 3 | Completed | Mar 6, 2026 | 1,454 |
| NCT05624450Respiratory Distress Syndrome · United States, Argentina, Australia and more | 3 | Recruiting | Nov 4, 2027 | 3,527 |
| NCT05166889Pulmonary Disease, Chronic Obstructive · United States, Argentina, Belgium and more | 3 | Completed | Jan 19, 2026 | 1,132 |
| NCT05158387Pulmonary Disease, Chronic Obstructive · United States, Australia, Brazil and more | 3 | Completed | Jan 19, 2026 | 1,172 |
| NCT05070312Healthy Volunteer · China | 1 | Completed | Feb 7, 2022 | 39 |
| NCT04631016Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada and more | 2 | Completed | May 30, 2023 | 137 |
| NCT04570657Asthma · United States, Argentina, Germany and more | 2 | Completed | Dec 12, 2022 | 250 |
| NCT04170543Diabetic Nephropathies · United States, Argentina, Canada and more | 2 | Completed | May 16, 2023 | 609 |
| NCT04212169Dermatitis, Atopic · United States, Australia, Germany and more | 2 | Completed | Jul 21, 2022 | 148 |
| NCT03096795Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | Sep 30, 2019 | 88 |
How it is read
Names in the registry
- “Tozorakimab”, 10 entries
- “MEDI3506”, 5 entries
- “Tozorakimab Dose Regimen 1”, 1 entry
- “Tozorakimab Dose Regimen 2”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 7 studies
- Asthma, 2 studies
- Respiratory Distress Syndrome, 1 study
- Bronchitis, Chronic, 1 study
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.